Ranbaxy loses battle for Lipitor patent in Canada.
Economic Times (New Delhi, India), September, 2007
Sep. 14--NEW DELHI -- In a setback for Ranbaxy in its global battle over the patent of Lipitor, a Canadian federal court has ruled that the company's generic drug Atorvastatin infringes upon one of Pfizer's Lipitor patent. However, the court dismissed Pfizer's appeal for a prohibition order for another patent of the same drug in Canada.
"The court has ruled that Pfizer's patent covering a crystalline form of Atorvastatin, the active ingredient in Lipitor, would be infringed by Ranbaxy's process for making their proposed generic Atorvastatin product," a Pfizer release said. The court ruling means that Ranbaxy cannot launch Atorvastatin in Canada until Lipitor's patent (Canadian Patent Number 22,20,018) expires in July 2016.
However, the court...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- LIFO vs. FIFO: a return to the basics
